<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>OBJECTIVE: Plasma <z:chebi fb="1" ids="6495">lipoprotein</z:chebi>-associated phospholipase A(2) (Lp-<z:chebi fb="79" ids="53407">PLA</z:chebi>(2)) levels predict incident <z:e sem="disease" ids="C0007222" disease_type="Disease or Syndrome" abbrv="CVD">cardiovascular disease</z:e>, impacting Lp-<z:chebi fb="79" ids="53407">PLA</z:chebi>(2) as an emerging therapeutic target </plain></SENT>
<SENT sid="1" pm="."><plain>We determined Lp-<z:chebi fb="79" ids="53407">PLA</z:chebi>(2) responses to <z:chebi fb="0" ids="35664">statin</z:chebi> and fibrate administration in type 2 <z:hpo ids='HP_0000819'>diabetes mellitus</z:hpo>, and assessed relationships of changes in Lp-<z:chebi fb="79" ids="53407">PLA</z:chebi>(2) with subclinical <z:mp ids='MP_0001845'>inflammation</z:mp> and <z:chebi fb="1" ids="6495">lipoprotein</z:chebi> characteristics </plain></SENT>
<SENT sid="2" pm="."><plain>METHODS: A placebo-controlled cross-over study (three 8-week treatment periods with <z:chebi fb="0" ids="9150">simvastatin</z:chebi> (40mg daily), <z:chebi fb="0" ids="47612">bezafibrate</z:chebi> (400mg daily) and their combination) was carried out in 14 male type 2 diabetic patients </plain></SENT>
<SENT sid="3" pm="."><plain>Plasma Lp-<z:chebi fb="79" ids="53407">PLA</z:chebi>(2) mass was measured by turbidimetric immunoassay </plain></SENT>
<SENT sid="4" pm="."><plain>RESULTS: Plasma Lp-<z:chebi fb="79" ids="53407">PLA</z:chebi>(2) decreased (-21±4%) in response to <z:chebi fb="0" ids="9150">simvastatin</z:chebi> (p&lt;0.05 from baseline and placebo), but was unaffected by <z:chebi fb="0" ids="47612">bezafibrate</z:chebi> (1±5%) </plain></SENT>
<SENT sid="5" pm="."><plain>The drop in Lp-<z:chebi fb="79" ids="53407">PLA</z:chebi>(2) during combined treatment (-17±3%, p&lt;0.05) was similar compared to that during <z:chebi fb="0" ids="9150">simvastatin</z:chebi> alone </plain></SENT>
<SENT sid="6" pm="."><plain>The Lp-<z:chebi fb="79" ids="53407">PLA</z:chebi>(2) changes during the 3 active <z:chebi fb="23" ids="18059">lipid</z:chebi> lowering treatment periods were related positively to baseline levels of high sensitive C-reactive protein, non-<z:chebi fb="4" ids="47775">HDL cholesterol</z:chebi>, <z:chebi fb="4" ids="17855">triglycerides</z:chebi>, the total cholesterol/<z:chebi fb="4" ids="47775">HDL cholesterol</z:chebi> ratio and less <z:chebi fb="15" ids="39026">LDL</z:chebi> electronegativity (p&lt;0.02 to p&lt;0.01), and inversely to baseline Lp-<z:chebi fb="79" ids="53407">PLA</z:chebi>(2) (p&lt;0.01) </plain></SENT>
<SENT sid="7" pm="."><plain>LpPLA(2) responses correlated inversely with changes in non-<z:chebi fb="4" ids="47775">HDL cholesterol</z:chebi>, <z:chebi fb="4" ids="17855">triglycerides</z:chebi> and the total cholesterol/<z:chebi fb="4" ids="47775">HDL cholesterol</z:chebi> ratio during treatment (p&lt;0.05 to p&lt;0.02) </plain></SENT>
<SENT sid="8" pm="."><plain>CONCLUSIONS: In type 2 <z:hpo ids='HP_0000819'>diabetes mellitus</z:hpo>, plasma Lp-<z:chebi fb="79" ids="53407">PLA</z:chebi>(2) is likely to be lowered by <z:chebi fb="0" ids="35664">statin</z:chebi> treatment only </plain></SENT>
<SENT sid="9" pm="."><plain>Enhanced subclinical <z:mp ids='MP_0001845'>inflammation</z:mp> and more severe <z:e sem="disease" ids="C0242339" disease_type="Disease or Syndrome" abbrv="">dyslipidemia</z:e> may predict diminished LpPLA(2) responses during <z:chebi fb="23" ids="18059">lipid</z:chebi> lowering treatment, which in turn appear to be quantitatively dissociated from decreases in <z:chebi fb="0" ids="39015">apolipoprotein</z:chebi> B <z:chebi fb="2" ids="6495">lipoproteins</z:chebi> </plain></SENT>
<SENT sid="10" pm="."><plain>Conventional <z:chebi fb="23" ids="18059">lipid</z:chebi> lowering treatment may be insufficient for optimal LpPLA(2) lowering in <z:hpo ids='HP_0000819'>diabetes mellitus</z:hpo> </plain></SENT>
</text></document>